TTY Biopharm Company Limited (TPEX:4105)

Market Cap	20.02B
Revenue (ttm)	6.22B
Net Income (ttm)	1.58B
Shares Out	248.65M
EPS (ttm)	6.35
PE Ratio	12.68
Forward PE	n/a
Dividend	4.20 (5.22%)
Ex-Dividend Date	Mar 27, 2025

Volume	1,094,170
Average Volume	588,348
Open	81.20
Previous Close	80.40
Day's Range	80.00 - 81.40
52-Week Range	66.20 - 82.00
Beta	-0.07
RSI	74.25
Earnings Date	Nov 4, 2025

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 342
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4105

Financial Performance

In 2024, TTY Biopharm Company's revenue was 5.89 billion, an increase of 7.05% compared to the previous year's 5.51 billion. Earnings were 1.45 billion, an increase of 28.45%.